The MEVPRO-2 Phase 3 Trial of Mevrometostat plus Enzalutamide in ARPI-Naive mCRPC - Neal Shore
Neal Shore
Neal Shore describes the MEVPRO-2 trial design, a 900-patient double-blind randomized study of mevrometostat 875 mg twice daily with food plus enzalutamide versus enzalutamide alone in ARPI-naive mCRPC patients.
ABBV-969, a Dual-Targeted PSMA-STEAP1 ADC in Heavily Pretreated mCRPC - Tanya Dorff
Tanya Dorff
Tanya Dorff presents phase 1 data on ABBV-969, a dual-targeting antibody-drug conjugate binding PSMA and STEAP1 to deliver a topoisomerase payload in 49 heavily pretreated mCRPC patients.
